about
Novel role of phosphodiesterase inhibitors in the management of end-stage heart failureAdvanced therapies for end-stage heart failureThe relationship between systolic blood pressure on admission and mortality in older patients with heart failure.Inotropes do not increase mortality in advanced heart failureShort-term mortality and cost associated with cardiac device implantation in patients hospitalized with heart failure.Renal Function and Outcomes With Use of Left Ventricular Assist Device Implantation and Inotropes in End-Stage Heart Failure: A Retrospective Single Center Study.Inotrope use and outcomes among patients hospitalized for heart failure: impact of systolic blood pressure, cardiac index, and etiologymiRNA expression in pediatric failing human heart.Background and design of the profiling biobehavioral responses to mechanical support in advanced heart failure study.Decision making in advanced heart failure: a scientific statement from the American Heart AssociationTherapeutic adjustments in stage D heart failure: challenges and strategies.Symptom management challenges in heart failure: pharmacotherapy considerations.Palliative care and hospice in advanced heart failure.Is Exercise Training Appropriate for Patients With Advanced Heart Failure Receiving Continuous Inotropic Infusion? A Review.Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure.A palliative approach for heart failure end-of-life care.Oral terbutaline in replacement for intravenous dopamine in a patient with end-stage heart failure.
P2860
Q26741100-4D59EE0B-D9D1-4AB5-B8C8-6AC9070A421FQ26992073-AE7C045B-445B-419E-B9F1-B5A13E4F9942Q33595656-82EF4908-9B68-423D-9CEF-3646813D9B54Q33685748-3E3E382C-B423-4B84-BE34-B39BFFB307CFQ33735354-A9D4AB3A-66C4-4229-9000-79532A410032Q33763311-BD2F00C5-AE09-4B2A-BABC-95B451C6708EQ35077700-28FB49EE-448E-48D1-8B38-9E6BCCE0D549Q36959812-8D266103-1462-45CC-9ED4-FFFF0EDDC2A5Q37452892-28E2EEFA-998F-4E8A-9BB7-E13097779428Q37486284-2A7C58D2-8972-4415-9694-D67AACC236C1Q38267665-E7643AC5-755A-43B7-8777-E4991AA54AEEQ39395575-B2BCE3B3-475C-411F-A87B-61A0504ED3C5Q42702187-572708F0-48F1-469F-8EB5-85699CB09C22Q47391460-4EB969B5-5BD8-442A-A3BF-98E2F8C4F66FQ47860273-978977B8-D954-4EA9-8436-DC1E4EE50400Q50030280-7F65C768-406C-45D7-BE67-1948A63E8CB2Q53920497-E8221863-42E4-403A-85E7-6ACEBDDAC263
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Chronic inotropic therapy in end-stage heart failure.
@ast
Chronic inotropic therapy in end-stage heart failure.
@en
type
label
Chronic inotropic therapy in end-stage heart failure.
@ast
Chronic inotropic therapy in end-stage heart failure.
@en
prefLabel
Chronic inotropic therapy in end-stage heart failure.
@ast
Chronic inotropic therapy in end-stage heart failure.
@en
P2093
P2860
P1476
Chronic inotropic therapy in end-stage heart failure.
@en
P2093
Anil George
Clinton J Mohr
Jason Swindle
Mark A Schnitzler
Paul J Hauptman
Peter Mikolajczak
Robert Hoover
P2860
P304
P356
10.1016/J.AHJ.2006.08.003
P407
P577
2006-12-01T00:00:00Z